4.7 Article

Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy

期刊

JOURNAL OF CLINICAL MEDICINE
卷 12, 期 20, 页码 -

出版社

MDPI
DOI: 10.3390/jcm12206667

关键词

kidney transplantation; difficult-to-treat rejection; T cell-mediated rejection; chronic antibody-mediated rejection; quadruple therapy; everolimus; graft survival

向作者/读者索取更多资源

This study retrospectively analyzed the data of 28 kidney transplant recipients who received everolimus-based quadruple therapy for difficult-to-treat rejections. The results showed a 5-year death-censored graft survival rate of 79% and a response rate of 43% in these patients. The 5-year patient survival rate was 94%. Despite some patients discontinuing treatment due to adverse events, this treatment approach may be effective for kidney transplant recipients with difficult-to-treat rejections.
All chronic and treatment-resistant acute rejections are difficult-to-treat and lead to progressive loss of graft function in kidney transplant recipients (KTR), as no effective treatment exists for such rejections to date. We review our experience with a novel strategy to treat such rejections by adding everolimus as a rescue to conventional triple maintenance therapy with prednisolone, mycophenolate mofetil and calcineurin inhibitor. We retrospectively analysed data in 28 KTR who received everolimus-based quadruple therapy at our institution for biopsy-proven chronic active T cell-mediated or antibody-mediated rejection (n = 19) or treatment-resistant acute rejections (n = 9) between 2011-2017. The primary outcome was 5-year death-censored graft survival. Main secondary outcomes were response to treatment defined by stable or improved graft function, 5-year patient survival and discontinuation rate of treatment. The Kaplan-Meier estimate for 5-year death-censored graft survival was 79% in all patients, 90% for patients with chronic active T cell-mediated rejections, 78% for chronic active antibody-mediated rejection and 67% for acute rejections. Response to treatment was achieved in 43% and 5-year patient survival was 94%. Treatment was stopped in 12 (43%) patients due to adverse events. Everolimus-based maintenance quadruple therapy, despite high rate of everolimus discontinuation due to adverse events, may be a valid approach in a subset of kidney transplant recipients with such difficult-to-treat rejections, which otherwise would lead to a high rate of graft loss.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据